Monofer (Ferric Derisomaltose)

Ferric derisomaltose, the active ingredient in Monofer, is an intravenous iron supplement presented as an injection solution for intravenous use. It is used to treat iron deficiency anemia in adults, including patients with chronic kidney disease or those requiring rapid iron repletion. GNH USA supplies Monofer as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Monofer is an intravenous iron formulation indicated for conditions involving iron deficiency and related anemia. - Iron deficiency anemia: restores hemoglobin levels and replenishes depleted iron stores. - Chronic kidney disease‑associated anemia: provides intravenous iron when oral supplementation is ineffective or not tolerated. - Perioperative anemia: rapidly corrects iron deficiency before surgery to reduce transfusion requirements.

Common Side Effects: - Nausea: mild to moderate stomach upset after infusion. - Headache: transient headache during or shortly after administration. - Dizziness: feeling light‑headed, especially with rapid infusion. - Injection site reactions: pain, erythema, or swelling at the infusion site. - Transient hypotension: temporary drop in blood pressure during infusion. - Metallic taste: brief metallic sensation in the mouth.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Severe hypotension: marked blood pressure decline that may need intervention. - Iron overload: excessive iron accumulation leading to organ toxicity. - Acute respiratory distress: sudden breathing difficulty post‑infusion. - Cardiac arrest: rare but life‑threatening cardiac event. - Stevens‑Johnson syndrome: severe skin and mucous membrane reaction.

Monofer should be administered only after confirming iron deficiency and evaluating the need for intravenous iron. - Assess iron status: verify ferritin and transferrin saturation before infusion. - Monitor hemoglobin: check levels during treatment to avoid excess iron. - Caution in hypersensitivity: avoid in patients with known allergy to ferric derisomaltose or other IV iron products. - Avoid during active infection: defer treatment if the patient has uncontrolled infection. - Observe during infusion: monitor blood pressure and signs of reaction throughout the administration. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Ferric derisomaltose may interact with other agents that affect iron metabolism or cause additive adverse effects. Major Interactions (Avoid): - Concurrent IV iron products: increases risk of iron overload and severe reactions. - Known severe allergy to ferric derisomaltose or iron dextran: may precipitate anaphylaxis. - High‑dose vitamin C administered intravenously: can increase free iron and oxidative stress. Moderate Interactions (Monitor Closely): - Erythropoiesis‑stimulating agents: may amplify blood pressure elevation. - Antihypertensive drugs: monitor for additive hypotensive effects during infusion. - Oral iron supplements: stagger dosing to prevent gastrointestinal irritation.